Adam Acosta
Partner, White & Case LLP
[email protected]
Adam Acosta is a partner in White & Case LLP’s Washington, DC, office and focuses on complex antitrust litigation, government investigations and related counselling.
Recognised by The Legal 500 in the antitrust cartel and antitrust class-action defence categories, Mr Acosta has ‘a strong reputation for successfully handling government investigations and litigating cartel/conspiracy antitrust cases, including a recent string of client wins in the pharmaceutical sector’ (The Legal 500: US, 2021). In 2022, he was named ‘MVP’ by Law360 in the life sciences category – the only attorney in the United States to receive that distinction for antitrust litigation.
Mr Acosta has litigated many of the major pharmaceutical antitrust matters over the past decade, including FTC v Actavis, AndroGel, Asacol, Bystolic, Doryx, Effexor, Lipitor, Loestrin, Zytiga and In re HIV Antitrust Litigation. He also routinely provides competition-related counselling to pharma clients involving competitor collaborations, patent-litigation settlements, drug-pricing and distribution practices, competitive intelligence, non-compete agreements and various other business initiatives in the pharmaceutical sector.